Effects of nucleos(t)ide analogues on renal function in patients with chronic hepatitis B

Abstract

Abstract:

AIM: To summarize the effects of nucleoside (acid) drugs on renal function in accepting antiviral therapy chronic hepatitis B patients. METHODS: Clinical data of 176 cases of chronic hepatitis B patients treated with nucleoside (acid) antiviral therapy (28 cases in ADV+LAM treatment group, 20 cases in ADV+ETV group, 21 cases in LAM group, 26 cases in ADV group, 81 cases in group ETV) were recorded, estimated glomerular filtration rate (eGFR) was calculated. The Kruskal-Wallis test or Mann-Whitney test or chi square difference test were used for comparative analysis of differences.RESULTS:The eGFR of the patients in ADV+LAM treatment group, ADV+ETV group, LAM group, ADV group and ETV group were (78.9±13.8),（80.2±15.8）,（78.8±12.9）,（74.6±14.6）,（79.5±13.1） mL·min-1·1.73 m-2, respectively, P>0.05; the number of cases with eGFR less than 80 mL·min-1·1.73 m-2 were 14(50%), 12(60%), 10(47.6%), 20(69.2%), 47（58.0%）, respectively, P＞0.05. Serum phosphorus levels were （0.95±0.14）,（0.92±0.11）,（1.02±0.13）,（0.92±0.16）,（0.97±0.14）mmol/L, respectively, P>0.05； the number of cases with a decreased serum phosphorus level were 15(53.6%), 13（65%）, 6（28.6%）, 13（50%）, 39（48.1%）, respectively; Furthermore, there were statistically significant differences between LAM group and ADV+ETV group (χ2=5.466 9, P=0.019 4). CONCLUSION: Long-term antiviral therapy of nucleoside (acid) drugs may affect renal function, in which the effect of ADV is the most obvious, ETV is the second, and LAM is the mildest. The monitoring of eGFR and serum phosphorus level is more sensitive to reveal the damage of kidney.

Key words: estimated glomerular filtration rate, renal damage, lamivudine, adefovir, entecavir

CLC Number:

R749

HUO Na, LU Haiying, WANG Guiqiang, HUANG Mingjie, WU Chihong, LIN Xiaohong. Effects of nucleos(t)ide analogues on renal function in patients with chronic hepatitis B[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(9): 1029-1034.

References

［1］Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B［J］. N Engl J Med, 1998,339(2):61-68.
［2］Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovirdipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years［J］. Gastroenterology, 2006,131(6):1743-1751.
［3］Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronichepatitis B［J］. N Engl J Med, 2007, 357(25):2576-2588.
［4］Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients withHBeAg-negative chronic hepatitis B［J］. N Engl J Med, 2006, 354(10):1011-1020.
［5］中华医学会肝病分会中华医学感染病学分会.慢性乙型肝炎防治指南［J］. 中国肝病学杂志, 2011, 19（1）：13-33.
［6］苏超，张桂霞，王瑞峰，等. CKD-EPI方程估算中国慢性肾脏病患者肾小球滤过率的适用性评价［J］.中华疾病控制杂志, 2013, 17(7):621-624.
［7］Perrillo R, Hann HW, Mutimer D, et al. Adefovirdipivoxil added to ongoing lamivudine inchronic hepatitis B with YMDD mutant hepatitis B virus［J］.Gastroenterology, 2004,126(1):81-90.
［8］Shimohata H,Sakai S,Ogawa Y, et al. Osteomalacia due to Fanconi's syndrome and renal failure caused by long-term low-doseadefovir dipivoxil［J］.Clin Exp Nephrol, 2013,17(1):147-148.
［9］Tanaka M, Setoguchi T, Ishidou Y, et al. Pathological femoral fractures due to osteomalacia associated withadefovir dipivoxiltreatment for hepatitis B: a case report［J］.Diagn Pathol, 2012，7:108.
［10］Li L, Dong GF, Zhang X, et al. Adefovir dipivoxil-induced Fanconi syndrome and hypophosphatemic osteomalacia associated with muscular weakness in a patient withchronic hepatitis B［J］.Nan Fang Yi Ke Da Xue Xue Bao,2011,31(11):1956.
［11］Sun XF, Zhang HB, Li XP, et al. A case ofadefovirdipivoxilinduced hypophosphataemicosteomalacia and literature review［J］. Zhonghua Nei Ke Za Zhi, 2011, 50(9):754-757.
［12］Gara N,Zhao X,Collins MT, et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy inchronic hepatitis B［J］.Aliment Pharmacol Ther, 2012, 35(11):1317-1325.
［13］Qi X,Wang JY,Mao RC, et al. Impact of nucleos(t)ide analogues on the estimated glomerular filtration rate in patients withchronic hepatitis B: a prospective cohort study in China［J］.J Viral Hepat,2015,22(1):46-54.
［14］Amarapurkar DN,Patel N.Increased eGFR withtelbivudinein combination therapy ofchronic hepatitis Binfection［J］.Indian J Gastroenterol,2014,33(1):89-91.
［15］Qi X,Wang J,Chen L, et al. Impact of nucleos(t)ide analogue combination therapy on the estimated glomerular filtration rate in patients with chronic hepatitis B［J］.Medicine (Baltimore),2015,94(15):e646.
［16］Wang X,Zhang C,Zhu Y, et al. Efficacy of 2years ofentecavirplus adefovir therapy in patients withchronic hepatitis Bwho had failed on prior nucleos(t)ide analog treatment［J］.Antiviral Res, 2014, 103:71-77.

[1]	ZENG Chuanli, HU Airong, HU Yaoren, YUAN Gang, ZHU Dedong, SHI Xiaojun. Clinical effect of entecavir combined with probiotics on treatment of patients with hepatitis B cirrhosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 796-801.
[2]	YUAN Gang, HU Airong, HU Yaoren, ZENG Chuanli, ZHU Dedong, SHI Xiaojun. Clinical efficacy and long-term prognosis of entecavir and adefovir dipivoxil in the treatment of compensatory hepatitis B cirrhosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 170-174.
[3]	ZOU Ming-zhi. Comparison of entecavir and adefovir dipivoxil on suppressing for the function of regulatory T cells for patients with chronic hepatitis B [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(6): 661-665.
[4]	LI Gui-qiu, CHEN Shu-lan, CUI Lan-ying, ZHAO Jin-ying, LUO Wen-tao, LU Juan. Comparison of the inhibitory effect on HBV replication by siRNA and lamivudine in HepG2.2.15 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(7): 727-731.
[5]	SUN Hua, ZHAO Ya-nan, GUO Yi-yun, LI Xiang-hong, YANG Jing-jing, MAO Guo-guang, XIE Hai-tang. Determination of lamivudine in human plasma by RP-HPLC and its application to bioequivalence research [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(2): 185-189.
[6]	PENG Guan-qing, ZHANG Chang, LIU Xue-feng. Clinical character of patients relapsed after withdrawal with lamivudine therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(10): 1166-1169.
[7]	CAO Dong-ping, PENG Ying-xin, YAO Wen-jing, RONG Chun-li, YU Wei, QIAO Shu-zhang. Effects of valsartan-hydrochlorothiazide combination on early renal damage of the patients with essential hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(5): 567-571.
[8]	LI Wen-li, WU Shi-pin. Efficacy of adefovir dipivoxil in treating patients with hepatitis B resistant to lamivudine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(7): 832-834.
[9]	LU Hai-ying, ZHUANG Li-wei, YU Yan-yan, SI Chong-wen, LI Jun, CHEN Xin-yue, HAN Zhong-hou, CHEN Yong. Role of intrahepatic HBV DNA in antivirus therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(3): 352-356.
[10]	David Z. D’ Argenio, WANG Xiao-ning, ZHOU Ze-xun. Application of Bayesian Methods for laboratory to clinical translation and for identifying hidden subpopulations [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(10): 1114-1121.
[11]	ZHANG Hong-He, SHAO Ting-Jun, YANG Zhong-Guo. Research on relation between genotype and effect of lamivudine in patient with hepatitis B virus infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(9): 1050-1053.
[12]	LI Wen-Li. Clinical evaluation of lamivudine in treatment of patients with chronic hepatitis B and asymptomatic carriers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(2): 198-200.
[13]	CHEN Hua-Zhong, ZHANG Jian-Bo. Effect of lamivudine on the quota of liver fi-brosis with cirrhosis infected by HBV [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(1): 77-77.